Christopher Bradley, MSc
Christopher Bradley, MSc is the CEO and Cofounder of Matter Bio, a pioneering longevity biotechnology company focused on extending human healthspan through advanced genetic interventions, and an Adjunct Professor in the Department of Technology Management and Innovation at NYU Tandon School of Engineering. He is also the CEO and Founder of Loki Therapeutics, an immuno-oncology company developing next-generation cancer therapeutics.
Chris is a serial entrepreneur with a background in both biology and technology, with over a decade of executive experience founding, funding, and operating complex and innovative healthcare and biotechnology businesses. His current mission is to increase healthy human longevity by addressing two related problems: treating advanced cancer when it already exists and preserving DNA information integrity to prevent disease from emerging.
In 2020, Chris cofounded Matter Bio alongside Harvard geneticist George Church, Jan Vijg of Albert Einstein College of Medicine, Claudia Gravekamp, Alexander Maslov, and Sam Sharifi. Matter Bio operates as a longevity holding company focused on preserving genome integrity, leveraging a hub-and-spoke model that advances multiple scientific breakthroughs each targeting a critical juncture of genomic information loss.
The company’s approach is based on the premise that aging is defined by damage incorporated into our DNA in the form of mutations, structural variations, epigenetic drift, and other types of information loss. Matter Bio employs a three-pronged strategy that first detects and identifies loss of genomic information, then corrects these mutations and reintroduces original genetic information, before finally eliminating cells too damaged to repair, such as cancerous, clonal, and senescent cells. Read Matter Bio: Learning from 400-Year-Old Sharks to Protect the Human Blueprint.
In 2024, Matter Bio successfully closed a $7 million seed funding round led by Lifespan Vision Ventures with contributions from quadraScope Ventures and additional support from grants by NIH, NCI, and NIEHS. In April 2025, Matter Bio announced the launch of a landmark longevity research collaboration, one of the most comprehensive efforts in aging science to date.
The initiative will analyze biological data from over 10,000 human centenarians and 20,000 members of their families, compared against over 200,000 regular human genome sequences. This data will be analyzed alongside samples from more than 300 long-lived and short-lived animal species, including the Greenland Shark, thought to be capable of living over 400 years. Read Matter Bio Successfully Closes $7M Seed Funding Round and Matter Bio Announces Landmark Collaboration to Decode Exceptional Longevity at Unprecedented Scale.
Chris is a coauthor of the peer-reviewed paper Mitigating age-related somatic mutation burden, published in Trends in Molecular Medicine in 2023, alongside George Church, Jan Vijg, Vadim N. Gladyshev, Vera Gorbunova, and other leading researchers in the aging field.
In 2019, Chris founded Loki Therapeutics, an immuno-oncology company developing a groundbreaking approach to cancer treatment through its proprietary AWAKE™ platform. The AWAKE technology activates and redirects pre-existing memory T cells created during childhood vaccination to target and eliminate cancer cells, using attenuated Listeria monocytogenes for the precise delivery of recall antigens to tumor environments.
Loki’s lead development program, AWAKE-LM-TT, focuses on the treatment of metastatic pancreatic and ovarian cancers. Chris has presented Loki’s clinical development strategy at the 2020 BIO Investor Forum and the BIO CEO & Investor Digital Conference in 2021. Listen to Making Cancer Look Like Something Else. Watch Loki Therapeutics – AWAKE™ Platform Technology.
Previously, Chris cofounded Mana Health in 2012, a health data interoperability startup that developed the ManaCloud platform to unify and integrate patient data from electronic medical records. Under his leadership as CEO, Mana Health deployed its technology to help more than 240 hospitals and serve 22 million patients. In 2018, Mana Health was acquired by Comcast NBCUniversal. Following the acquisition, Chris served as Executive Director of Product & Data Management at Comcast between 2018 and 2019, where he helped lead new initiatives and entity formation. Read Out to create health IT’s nervous system: Mana Health CEO Chris Bradley on the future of interoperability.
Chris earned his Master’s Degree of Science in Computer Science from NYU Tandon School of Engineering. He earned his Bachelor’s Degree of Science in Neuroscience and Cell Biology from Rutgers University. During his studies, Chris conducted undergraduate research in biomedical engineering at Rutgers University between 2007 and 2009, working on spinal cord regeneration and neuronal regrowth direction through haptotactic cues.
He conducted graduate research in fMRI imaging at Columbia University Irving Medical Center between 2009 and 2011, working with Xian Zhang, PhD on a mathematical model for dynamic decision making. Between 2010 and 2012, he conducted graduate research on dynamic multi-modal real-time fMRI at NYU Tandon School of Engineering, developing image recognition and processing pipelines for advanced experiment design and analysis.
Between 2021 and 2026, Chris served as an Adjunct Professor at New York University. He was a Fellow at the On Deck Longevity Biotech Fellowship between 2021 and 2023. He also served as an Advisor at Particle Health.
Chris is a nationally recognized thought leader and innovator who has contributed to healthcare conversations at the White House and the Office of the National Coordinator for Health IT. He has spoken at TEDxNYU in 2012 on the topic of healthcare interoperability. He has received various awards for his work, including the NYU Presidential Service Award. Watch Synthetic Biology: This Will Change Everything: Christopher Bradley at TEDxNYU.
He was a member of the CommonWell Health Alliance and HIMSS during his time at Mana Health. Chris has published articles in Becker’s Hospital Review, MedCity News, HIMSS Future Care, and intrepidNow Healthcare.
Chris is fluent in English and French. He grew up in Hawaii and is based in New York City.
Visit his LinkedIn profile, NYU Faculty page, and Matter Bio Homepage. Follow him on X.